Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651807 | 0.92 | MAPT (0.48) | MAPTSMN1; SMN2GAAKDM4EALDH1A1 | |
| SCHEMBL27534253 | 0.91 | MAPT (0.52) | MAPTSMN1; SMN2GAAKDM4EALDH1A1 | |
| SCHEMBL6650847 | 0.90 | MAPT (0.54) | MAPTSMN1; SMN2GAAKDM4EALDH1A1 | |
| SCHEMBL6653788 | 0.89 | MAPT (0.57) | MAPTSMN1; SMN2GAAKDM4EALDH1A1 | |
| SCHEMBL6652000 | 0.88 | KDM4E (0.50) | MAPTSMN1; SMN2GAAKDM4EALDH1A1 | |
| SCHEMBL6674884 | 0.87 | GFER (0.40) | MAPTSMN1; SMN2GAAKDM4EALDH1A1 | |
| SCHEMBL6650199 | 0.87 | ALDH1A1 (0.51) | MAPTSMN1; SMN2GAAKDM4EALDH1A1 | |
| SCHEMBL7039443 | 0.85 | MAPT (0.40) | MAPTSMN1; SMN2GAAKDM4ECYP2C19 | |
| SCHEMBL6651711 | 0.85 | ALDH1A1 (0.52) | MAPTSMN1; SMN2GAAKDM4EALDH1A1 | |
| SCHEMBL6649606 | 0.84 | SMN1; SMN2 (0.49) | MAPTSMN1; SMN2GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1424072-A1 | N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors | Samjin Pharmaceutical Co., Ltd. (KR) | 2004-06-02 | — | — | EP | disclosed |
| US-6683184-B2 | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | MAPT 4877/4885SMN1; SMN2 2466/4885GAA 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.